Aeterna Zentaris Inc.

Equities

AEZS

CA0079756007

Biotechnology & Medical Research

End-of-day quote Toronto S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
11.57 ^CAD	+0.17%		+4.61%	+12.55%

May. 17	Aeterna Zentaris Finalizes Some Details for Ceapro Merger	MT
May. 17	Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	MT

Aeterna Zentaris Announces Appointment of Jeffrey Whitnell as Interim Chief Financial Officer

September 25, 2017 at 04:30 pm EDT

Aeterna Zentaris Inc. announced that effective, September 25, 2017, Jeffrey Whitnell has been appointed to the position of Interim Chief Financial Officer. Most recently, he served as Vice-President, Finance & Controller of Lifewatch Services Inc.

Latest news about Aeterna Zentaris Inc.

Aeterna Zentaris Finalizes Some Details for Ceapro Merger	May. 17	MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	May. 17	MT
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden	May. 14	MT
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	Mar. 28	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	Mar. 28	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	Mar. 27	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	Mar. 27	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	Mar. 27	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	Feb. 26	MT
Traders Search for Fresh Cues After Fed-Driven Rally as US Equity Futures Waver Pre-Bell	Dec. 18	MT
Top Premarket Gainers	Dec. 18	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	Dec. 14	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	Dec. 14	MT
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 20 million in a merger of equals transaction.	Nov. 28	CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	Nov. 16	DJ
HC Wainwright Cuts Aeterna Zentaris' Price Target to $15 From $28, Maintains Buy Rating	Nov. 13	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Aeterna Zentaris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI

Chart Aeterna Zentaris Inc.

Duration

Period

More charts

Company Profile

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

Sector

Biotechnology & Medical Research

Calendar

2024-07-01 - Annual General Meeting

More about the company

	1st Jan change	Capi.
AETERNA ZENTARIS INC.	+12.55%	10.32M
MODERNA, INC.	+41.79%	54.04B
LONZA GROUP AG	+47.02%	41.96B
IQVIA HOLDINGS INC.	-0.56%	41.92B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B

Other Biotechnology & Medical Research

Aeterna Zentaris Inc.

Equities

AEZS

CA0079756007

Biotechnology & Medical Research

Aeterna Zentaris Announces Appointment of Jeffrey Whitnell as Interim Chief Financial Officer

Latest news about Aeterna Zentaris Inc.

Chart Aeterna Zentaris Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research